{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:07:12Z","timestamp":1791270432883,"version":"4.1.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background\/aims<\/jats:title><jats:p>The metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity are frequent comorbidities with a high prevalence worldwide. Their pathogenesis are multifactorial, including intestinal dysbiosis. The role of small intestinal bacterial overgrowth (SIBO) in MASLD progression in obese patients remains unknown. We aimed to determine the association between SIBO and the severity of MASLD in obese patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An observational and cross-sectional study was conducted in obese patients, diagnosed with or without MASLD by liver biopsy. Metabolic dysfunction-associated steatotic liver (MASL), metabolic dysfunction-associated steatohepatitis without fibrosis (MASH-NF), MASH with fibrosis (MASH-F), or without MASLD (control subjects, CS) were identified by presence of steatosis, portal and lobular inflammation, and fibrosis. SIBO was determined by standardized lactulose breath tests.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 59 patients with MASLD, 16 with MASL, 20 with MASH-NF, 23 with MASH-F, and 14 CS were recruited. Higher percentages of SIBO were observed in MASLD patients (44.2%) compared to CS (14.2%; <jats:italic>p<\/jats:italic> = 0.0363). Interestingly, MASH-F showed higher percentages of SIBO (65.2%) in comparison to non-fibrotic MASLD (33.3%; <jats:italic>p<\/jats:italic> = 0.0165). The presence of SIBO was not correlated with the level of hepatic steatosis in MASLD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A positive correlation between MASLD and SIBO in obese patients was principally explained by the presence of liver fibrosis. Our findings suggest a pathogenic role of intestinal dysbiosis in the progression of MASLD. Future research will elucidate the underlying mechanisms of SIBO in MASLD advancement.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1376148","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T04:45:50Z","timestamp":1716525950000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Small intestinal bacterial overgrowth in obese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: a cross-sectional study"],"prefix":"10.3389","volume":"11","author":[{"given":"Nicol\u00e1s","family":"Ortiz-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"Madrid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Aleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Zazueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gladys","family":"Smok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Valenzuela-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Poniachik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroll J.","family":"Beltr\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"E93","DOI":"10.1097\/HEP.0000000000000696","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2024","journal-title":"Hepatology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3350\/cmh.2020.0129","article-title":"The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease","volume":"27","author":"Jennison","year":"2021","journal-title":"Clin Mol Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"115546","DOI":"10.1016\/j.bcp.2023.115546","article-title":"The role of small intestinal bacterial overgrowth in obesity and its related diseases","volume":"212","author":"Yao","year":"2023","journal-title":"Biochem Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.7570\/jomes22021","article-title":"Recent epidemiology and risk factors of nonalcoholic fatty liver disease","volume":"31","author":"Huh","year":"2022","journal-title":"J Obes Metab Syndr."},{"key":"B7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"Pouwels","year":"2022","journal-title":"BMC Endocr Disord."},{"key":"B8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.cld.2017.08.007","article-title":"Pathophysiology of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"22","author":"Manne","year":"2018","journal-title":"Clin Liver Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"954869","DOI":"10.3389\/fimmu.2022.954869","article-title":"The immune response as a therapeutic target in non-alcoholic fatty liver disease","volume":"13","author":"Ortiz-L\u00f3pez","year":"2022","journal-title":"Front Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"660179","DOI":"10.3389\/fimmu.2021.660179","article-title":"The role of the gut-liver axis in metabolic dysfunction-associated fatty liver disease","volume":"12","author":"Mart\u00edn-Mateos","year":"2021","journal-title":"Front Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s00535-019-01649-8","article-title":"Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives","volume":"55","author":"Hu","year":"2020","journal-title":"J Gastroenterol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"729950","DOI":"10.3389\/fphar.2021.729950","article-title":"Probiotics-based treatment as an integral approach for alcohol use disorder in alcoholic liver disease","volume":"12","author":"Fuenzalida","year":"2021","journal-title":"Front Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"666","DOI":"10.5009\/gnl20032","article-title":"Leaky gut and gut-liver axis in liver cirrhosis: clinical studies update","volume":"15","author":"Fukui","year":"2021","journal-title":"Gut Liver."},{"key":"B14","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.cyto.2006.02.006","article-title":"Increased production of IL-1\u03b1 and TNF-\u03b1 in lipopolysaccharide-stimulated blood from obese patients with non-alcoholic fatty liver disease","volume":"33","author":"Poniachik","year":"2006","journal-title":"Cytokine."},{"key":"B15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.freeradbiomed.2018.05.084","article-title":"Autophagy and oxidative stress in non-communicable diseases: a matter of the inflammatory state?","volume":"124","author":"Pe\u00f1a-Oyarzun","year":"2018","journal-title":"Free Radic Biol Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1097\/MEG.0000000000001541","article-title":"Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"32","author":"Wijarnpreecha","year":"2020","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B17","first-page":"112","article-title":"Small intestinal bacterial overgrowth: a comprehensive review","volume":"3","author":"Dukowicz","year":"2007","journal-title":"Gastroenterol Hepatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e0234906","DOI":"10.1371\/journal.pone.0234906","article-title":"The duodenal microbiome is altered in small intestinal bacterial overgrowth","volume":"15","author":"Leite","year":"2020","journal-title":"PLOS ONE."},{"key":"B19","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.3390\/ijms25084387","article-title":"Alteration of gut microbiota composition in the progression of liver damage in patients with metabolic dysfunction- associated steatotic liver disease (MASLD)","volume":"25","author":"Zazueta","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3390\/ijms17060928","article-title":"Effects of probiotics and synbiotics on obesity, insulin resistance syndrome, type 2 diabetes and non-alcoholic fatty liver disease: a review of human clinical trials","volume":"17","author":"S\u00e1ez-Lara","year":"2016","journal-title":"Int J Mol Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1042\/CS20030285","article-title":"Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients","volume":"106","author":"Videla","year":"2004","journal-title":"Clin Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10620-010-1239-9","article-title":"Small intestinal clustered contractions and bacterial overgrowth: a frequent finding in obese patients","volume":"56","author":"Madrid","year":"2011","journal-title":"Dig Dis Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.15403\/jgld.2014.1121.252.iwg","article-title":"Small intestinal bacterial overgrowth is associated with non- alcoholic fatty liver disease","volume":"25","author":"Fialho","year":"2016","journal-title":"J Gastrointestin Liver Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s11695-007-9398-2","article-title":"High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis","volume":"18","author":"Sabat\u00e9","year":"2008","journal-title":"Obes Surg."},{"key":"B25","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/hep.32197","article-title":"Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease","volume":"75","author":"Kwan","year":"2022","journal-title":"Hepatology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.4067\/S0034-98872021000901360","article-title":"Resumen ejecutivo: enfermedad por h\u00edgado graso no alcoh\u00f3lico en sujetos con diabetes mellitus tipo 2: postura conjunta de la Asociaci\u00f3n Chilena de Hepatolog\u00eda (ACHHEP) y la Sociedad Chilena de Diabetolog\u00eda (SOCHIDIAB)","volume":"149","author":"Arab","year":"2021","journal-title":"Rev M\u00e9d Chile."},{"key":"B27","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.3350\/cmh.2022.0424","article-title":"Non-alcoholic fatty liver disease: definition and subtypes","volume":"29","author":"Han","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/s41467-023-35861-1","article-title":"Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2-oleoylglycerol","volume":"14","author":"Yang","year":"2023","journal-title":"Nat Commun."},{"key":"B29","doi-asserted-by":"publisher","first-page":"571847","DOI":"10.3389\/fmicb.2020.571847","article-title":"Gut microbiome contributes to liver fibrosis impact on T cell receptor immune repertoire","volume":"11","author":"Liang","year":"2020","journal-title":"Front Microbiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"968799","DOI":"10.3389\/fimmu.2022.968799","article-title":"The contribution of the gut-liver axis to the immune signaling pathway of NAFLD","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.3892\/etm.2019.7781","article-title":"Role and effective therapeutic target of gut microbiota in NAFLD\/NASH","volume":"18","author":"Liu","year":"2019","journal-title":"Exp Ther Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"570","DOI":"10.4067\/s0034-98872021000400570","article-title":"Rol de la microbiota intestinal en el desarrollo del h\u00edgado graso no alcoh\u00f3lico","volume":"149","author":"Tumani","year":"2021","journal-title":"Rev M\u00e9d Chile."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1113643","DOI":"10.3389\/fcimb.2023.1113643","article-title":"Characterization of gut dominant microbiota in obese patients with nonalcoholic fatty liver disease","volume":"13","author":"Jin","year":"2023","journal-title":"Front Cell Infect Microbiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3350\/cmh.2020.0125","article-title":"Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis.","volume":"27","author":"Lee","year":"2021","journal-title":"Clin Mol Hepatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"869446","DOI":"10.3389\/fphar.2022.869446","article-title":"Just drink a glass of water? Effects of bicarbonate\u2013sulfate\u2013calcium\u2013magnesium water on the gut\u2013liver axis","volume":"13","author":"Gravina","year":"2022","journal-title":"Front Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.clnesp.2023.07.008","article-title":"The use of bicarbonate-sulphate-calcium-magnesium and sodium-low drinkable water improves functional gastrointestinal symptoms in patients with non-alcoholic fatty liver disease: a prospective study","volume":"57","author":"Gravina","year":"2023","journal-title":"Clin Nutr ESPEN."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3390\/nu15061323","article-title":"Small intestinal bacterial overgrowth and non-alcoholic fatty liver disease: what do we know in 2023?","volume":"15","author":"Gudan","year":"2023","journal-title":"Nutrients."},{"key":"B38","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/MEG.0000000000000348","article-title":"Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease","volume":"27","author":"Gangarapu","year":"2015","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1002\/hep.22848","article-title":"Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease","volume":"49","author":"Miele","year":"2009","journal-title":"Hepatology."},{"key":"B40","doi-asserted-by":"publisher","first-page":"294","DOI":"10.17235\/reed.2019.5942\/2018","article-title":"An assessment of bacterial overgrowth and translocation in the non-alcoholic fatty liver of patients with morbid obesity","volume":"111","author":"Domper Bardaj\u00ed","year":"2019","journal-title":"Rev Esp Enfermedades Dig"},{"key":"B41","doi-asserted-by":"publisher","first-page":"872428","DOI":"10.3389\/fmed.2022.872428","article-title":"The apparent asymmetrical relationship between small bowel bacterial overgrowth, endotoxemia, and liver steatosis and fibrosis in cirrhotic and non-cirrhotic patients: a single-center pilot study","volume":"9","author":"Scarpellini","year":"2022","journal-title":"Front Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1590\/s0004-2803.202000000-82","article-title":"Peripheral blood endotoxin levels are not associated with small intestinal bacterial overgrowth in nonalcoholic fatty liver disease without cirrhosis","volume":"57","author":"Guimar\u00e3es","year":"2020","journal-title":"Arq Gastroenterol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5056\/jnm19113","article-title":"Breath tests for the non-invasive diagnosis of small intestinal bacterial overgrowth: a systematic review with meta-analysis","volume":"26","author":"Losurdo","year":"2020","journal-title":"J Neurogastroenterol Motil."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1376148\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T04:45:53Z","timestamp":1716525953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1376148\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":43,"alternative-id":["10.3389\/fmed.2024.1376148"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1376148","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,24]]},"article-number":"1376148"}}